Synonyms: GNE-684
Compound class:
Synthetic organic
Comment: GNE684 is an oral preclinical inhibitor of receptor interacting serine/threonine kinase 1 (RIPK1) [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Kist M, Kőműves LG, Goncharov T, Dugger DL, Yu C, Roose-Girma M, Newton K, Webster JD, Vucic D. (2021)
Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. Cell Death Differ, 28 (3): 985-1000. [PMID:32999468] |
2. Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, Dugger DL, Wickliffe KE, Maltzman A, Sujatha-Bhaskar S et al.. (2020)
RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ, 27 (1): 161-175. [PMID:31101885] |
3. Prado-Acosta M, Jeong S, Utrero-Rico A, Goncharov T, Webster JD, Holler E, Morales G, Dellepiane S, Levine JE, Rothenberg ME et al.. (2023)
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects. Sci Transl Med, 15 (727): eadf8366. [PMID:38117900] |